Entering a new life sciences vertical rarely means starting from a blank slate. The strongest positioning starts by inventorying the infrastructure, certifications, and geographic footprint an organization already has — then overlaying independent market research to find where real, addressable demand already sits inside existing capability.
Building the narrative before proof points exist is the job. That means the narrative has to be defensible on public data alone, long before there's a signed logo to point to.
The market-entry case that survives diligence is the one built on what an organization can already do, layered with independent data about where demand is heading — not a greenfield pitch that assumes a blank slate.
Catalog the infrastructure, certifications, and geographic presence that already exist — before assuming anything is "new."
Layer independent, third-party market research onto that footprint, region by region, to find where addressable demand already sits.
Identify the regulatory, certification, or capability requirement that's genuinely hard for a new entrant to replicate quickly.
Build and pressure-test the strategic case on public data alone — strong enough to earn the first conversation before a single logo exists.
A generalized first-principles market-entry framework for emerging life science verticals.
Established BioPharma testing providers are already executing exactly this playbook in cell & gene therapy. Eurofins BioPharma Product Testing has publicly described growing its CGT footprint from an initial 2010 program at its Lancaster, PA site into a dedicated 4,000-square-foot ATMP lab (2023) plus a second site in Columbia, MO — capability layered onto existing infrastructure rather than built from scratch.
That's the pattern this framework generalizes from: real, publicly documented, and repeatable across the industry — not tied to any single company's unpublished strategy.
Eurofins BPT, public announcement →A market case built entirely on independent, citable data survives scrutiny even when there's no reference customer yet.
Starting from what already exists — not what could theoretically be built — keeps the narrative grounded and executable.
Overlaying market data region by region, rather than at a single global figure, surfaces where the real near-term opportunity sits.
Knowing exactly which regulatory or capability requirement creates real competitive separation — not just asserting one exists.
First-principles market mapping for emerging life science verticals — built to earn the first conversation on public data alone, before there's a case study to point to.